Technical Analysis for ALIM - Alimera Sciences, Inc.

Grade Last Price % Change Price Change
B 4.00 -4.99% -0.21
ALIM closed down 4.99 percent on Monday, March 18, 2024, on 1.29 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
Cup with Handle Other 0.00%
Upper Bollinger Band Walk Strength 0.00%
Inside Day Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Expansion Pivot Buy Setup Bullish Swing Setup -4.99%
Pocket Pivot Bullish Swing Setup -4.99%
Volume Surge Other -4.99%
Stochastic Reached Overbought Strength -4.99%
Above Upper BB Strength -4.99%

   Recent Intraday Alerts

Alert Time
Down 5% about 14 hours ago
Possible Inside Day about 14 hours ago
Down 1 ATR about 14 hours ago
60 Minute Opening Range Breakdown about 17 hours ago
Down 3% about 17 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Alimera Sciences, Inc. Description

Alimera Sciences, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company's principal product candidate is ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye to a placement site that takes advantage of the eye's natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). The company has completed Phase III pivotal clinical trials for the treatment of DME; and in Phase II clinical trials for the treatment of the dry form of age-related macular degeneration and retinal vein occlusion. It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN; and Dainippon Sumitomo Pharma Co., Ltd. for the development, manufacture, and marketing of an injectable polymer tube implantable into an eye containing a mixture of a polymer and FAc. Alimera Sciences, Inc. was founded in 2003 and is based in Alpharetta, Georgia.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: Medicine Biopharmaceutical Disease Organ Systems Diabetes Eye Ophthalmic Macular Degeneration Macular Edema Diabetic Retinopathy Retina Veins Diabetic Macular Edema Blindness Age Related Macular Degeneration Fluid Dynamics Glucocorticoids Pivotal Corticosteroid Pregnanes Diketones Fluocinolone Retinal Vein Occlusion

Is ALIM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.38
52 Week Low 1.33
Average Volume 81,239
200-Day Moving Average 3.40
50-Day Moving Average 3.77
20-Day Moving Average 3.68
10-Day Moving Average 3.91
Average True Range 0.26
RSI (14) 57.81
ADX 21.94
+DI 22.17
-DI 10.70
Chandelier Exit (Long, 3 ATRs) 3.50
Chandelier Exit (Short, 3 ATRs) 3.84
Upper Bollinger Bands 4.22
Lower Bollinger Band 3.14
Percent B (%b) 0.8
BandWidth 29.14
MACD Line 0.09
MACD Signal Line 0.04
MACD Histogram 0.054
Fundamentals Value
Market Cap 209.67 Million
Num Shares 52.4 Million
EPS -1.65
Price-to-Earnings (P/E) Ratio -2.42
Price-to-Sales 3.00
Price-to-Book 4.14
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.47
Resistance 3 (R3) 4.50 4.38 4.39
Resistance 2 (R2) 4.38 4.26 4.36 4.36
Resistance 1 (R1) 4.19 4.19 4.13 4.16 4.34
Pivot Point 4.07 4.07 4.04 4.05 4.07
Support 1 (S1) 3.88 3.95 3.82 3.85 3.66
Support 2 (S2) 3.76 3.88 3.74 3.64
Support 3 (S3) 3.57 3.76 3.61
Support 4 (S4) 3.54